Antithrombin III increases survival in high-risk sepsis patients

Inpharma 1533 - 15 Apr 2006

Antithrombin III increases survivalin high-risk sepsis patients

High-dose antithrombin III (ATIII) may increasesurvival in patients with severe sepsis and a high risk ofdeath, and could be even more effective withoutconcurrent heparin treatment, according to an analysisof the multicentre KyberSept trial*.

Data were evaluated from 1008 patients from theKyberSept population with severe sepsis and a SAPS II**-predicted mortality rate of between 30% and 60%. Thesepatients had been randomised to receive either IV ATIII30 000 IU over 4 days (n = 490) or placebo.

The survival rates were significantly higher over90 days in ATIII-treated patients, compared with placeborecipients. In addition, ATIII-treated patients who didnot receive concurrent heparin treatment showed aneven greater improvement in survival rate over 90 days,compared with placebo recipients. There was asignificantly higher incidence of bleeding events inpatients who received ATIII, especially those treatedwith heparin, compared with patients in the placebogroup. Notably, the increase in frequency of bleedingevents in the ATIII-treated patients did not affect thesignificantly greater survival rate in this group.* See Inpharma 1311 p11; 800840911; partially supported by ZLBBehring GmBH, Germany** Simplified Acute Physiology Score II

Wiedermann CJ, et al. High-dose antithrombin III in the treatment of severe sepsisin patients with a high risk of death: efficacy and safety. Critical Care Medicine34: 285-292, No. 2, Feb 2006 801036324

1

Inpharma 15 Apr 2006 No. 15331173-8324/10/1533-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved